Which Indian biotechnology company developed the first indigenous mRNA vaccine for COVID-19, with support from DBT and BIRAC?
Show answer & explanation
Correct answer: B
Explanation
Correct Answer:
Gennova Biopharmaceuticals Ltd.
Explanation:
India's first indigenous mRNA vaccine for COVID-19, named GEMCOVAC-19, was developed by Pune-based Gennova Biopharmaceuticals Ltd. This landmark achievement was provided substantial financial and technical support by the Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC) under 'Mission COVID Suraksha'.
Unlike traditional vaccines (which introduce weakened or inactivated viruses), mRNA vaccines deliver a small piece of genetic code (mRNA) to the body. This code instructs our cells to make a harmless 'spike protein' found on the virus, activating the body's immune system and triggering the production of antibodies. The biggest advantage of Gennova's vaccine is that it can be stored at normal refrigerator temperatures (2°C to 8°C), eliminating the need for ultra-cold storage infrastructure (70°C) like Western vaccines like Pfizer and Moderna.
Key Points
This vaccine (GEMCOVAC-19) uses a unique 'self-amplifying mRNA' technology, which requires a much lower dose to generate a strong immune response. Its ability to remain safe at room temperature makes this vaccine highly suitable for distribution in rural and remote areas. Gennova later developed the country's first booster vaccine, 'GEMCOVAC-OM,' against the Omicron variant using this technology.
Key Questions and Answers
Question: What is the official commercial name of the first indigenous mRNA COVID-19 vaccine developed in India?
Answer: GEMCOVAC-19.
Question: Compared to Western countries, at what temperature range is this mRNA vaccine from India stable, making it suitable for rural Indian areas?
Answer: 2°C to 8°C (normal refrigeration temperatures)